BioAge Labs (BIOA) Preferred Stock Liabilities (2023 - 2024)
BioAge Labs' (BIOA) quarterly Preferred Stock Liabilities came in at $342.8 million in Q2 2024, little changed quarter-over-quarter from $342.8 million in Q1 2024.
Powered by 
Analysis
BioAge Labs (BIOA) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
BioAge Labs has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $342.8 million for Q2 2024.
- In Q2 2024, Preferred Stock Liabilities changed N/A year-over-year to $342.8 million; the TTM figure through Jun 2024 stood at $342.8 million (changed N/A YoY), while the FY2023 annual figure was $132.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $342.8 million for Q2 2024 at BioAge Labs, roughly flat from $342.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $342.8 million in Q1 2024 to a low of $132.7 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 342.83 Mn |
| Mar 31, 2024 | 342.83 Mn |
| Dec 31, 2023 | 132.72 Mn |
| Sep 30, 2023 | 132.72 Mn |